My understanding is that Prof Sinclair resigned on the Board, but remains in management as the Chief Scientific Officer. https://invextherapeutics.com/directors-management/
If the remaining BoD members and Tattarang is smart, they will realise that the value of Presendin and Invex's patent portfolio is reliant on Professor Sinclair.
So if they plan to continue with a scientific program post mid Q3, they will need to create a compelling salary package and incentive program to keep her in the company.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-28
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.711M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29539 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.2¢ | 79447 | 1 |
View Market Depth
| Last trade - 10.04am 22/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable